Clinical results of combined treatment conformal high-dose-rate iridium-192 brachytherapy and external beam radiotherapy using staging lymphadenectomy for localized prostate cancer

International Journal of Radiation Oncology Biology Physics

Volumn 59, Issue 3, 2004, Pages 684-690

  Hiratsuka, Junichi ^a   Jo, Yoshimasa ^a   Yoshida, Kenji ^a   Nagase, Naomi ^a   Fujisawa, Masato ^a   Imajo, Yoshinari ^a  

^a KAWASAKI MEDICAL SCHOOL   (Japan)

Author keywords

Clinical outcome; High dose rate brachytherapy; Localized prostate cancer; Radiotherapy

Indexed keywords

BIOCHEMISTRY; DRUG DOSAGE; HORMONES; ONCOLOGY; PATIENT TREATMENT; RADIOTHERAPY; TUMORS;

BRACHYTHERAPY; HORMONAL THERAPY; PROSTATE CANCER;

MEDICAL IMAGING;

ANTIANDROGEN; CONTRAST MEDIUM; GONADORELIN; IRIDIUM 192; PROSTATE SPECIFIC ANTIGEN;

ACUTE TOXICITY; ADULT; AGED; ARTICLE; BEAM THERAPY; BLADDER DISEASE; BRACHYTHERAPY; CANCER HORMONE THERAPY; CANCER STAGING; CAUSE OF DEATH; CHRONIC TOXICITY; CYSTITIS; DIARRHEA; DRUG MEGADOSE; DYSURIA; FOLLOW UP; HIGH RISK PATIENT; HUMAN; INCONTINENCE; JAPAN; LIVER CELL CARCINOMA; LYMPH NODE METASTASIS; LYMPHADENECTOMY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROCTITIS; PROSTATE ADENOCARCINOMA; RECTUM HEMORRHAGE; RISK FACTOR; STOMACH CANCER; TREATMENT FAILURE; URETHRA STRICTURE;

AGED; AGED, 80 AND OVER; BRACHYTHERAPY; COMBINED MODALITY THERAPY; HUMANS; IRIDIUM RADIOISOTOPES; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIATION INJURIES; RADIOTHERAPY DOSAGE; RADIOTHERAPY, CONFORMAL; RECTUM; URINARY BLADDER;

EID: 2942528789     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2003.11.035     Document Type: Article

References (28)

1. Brachman D.G., Thomas T., Hilbe J., et al. Failure-free survival following brachytherapy alone for T1-2 prostate tumors in 2222 patients Results from a single practice. Int J Radiat Oncol Biol Phys. 48:2000;111-117
2. 125I prostate implantation. Int J Radiat Oncol Biol Phys. 37:1997;559-563
3. Wallner K., Roy J., Harrison L. Tumor control and morbidity following transperineal iodine 125I implantation for stage T1/T2 prostate carcinoma. J Clin Oncol. 14:1996;449-453
4. Blasko J.C., Wallner K., Grimm P.D., et al. Prostate specific antigen based disease control following ultrasound guided I-125 implantation for stage T1/T2 prostatic carcinoma. J Urol. 154:1995;1096-1099
5. Radge H., Elgamal A.A., Snow P.B., et al. Ten-year disease free survival after transperineal sonography-guided iodine-125 brachytherapy with or without 45-Gray external beam irradiation in the treatment of patients with clinically localized, low to high Gleason grade prostate carcinoma. Cancer. 83:1998;989-1001
6. Bertermann H., Brix F. Ultrasonically guided interstitial high dose rate brachytherapy with Ir-192: Technique and preliminary results in locally confined prostate cancer. Martinez A.A., Orton C.G., Mould R. Brachytherapy HDR and LDR Remote afterloading state of art. 1990;281-303 Nucletron International BV, Leerson, The Netherlands
7. Mate T.P., Kwiatkowski T.M., Hatton J.W. Remote HDR afterloading brachytherapy of the prostate A preliminary report. Act Selectron Brachyther J. 4:1990;65-67
8. Martinez A.A., Gonzalez J., Stronberg J., et al. Conformal prostate brachytherapy Initial experience of a phase I-II dose-escalation trial. Int J Radiat Oncol Biol Phys. 33:1995;1019-1027
9. Yoshioka Y., Nose T., Yoshida K., et al. High-dose-rate interstitial brachytherapy as a monotherapy for localized prostate cancer Treatment description and preliminary results of a phase I/II clinical trial. Int J Radiat Oncol Biol Phys. 48:2000;675-681
10. Hanks G.E., Buzydlowski J., Sause W.T., et al. Ten-year outcomes for pathologic node-positive patients treated in RTOG 75-06. Int J Radiat Oncol Biol Phys. 40:1998;765-768
11. Asbell S.O., Martz K.L., Shin K.H., et al. Impact of surgical staging in evaluating the radiotherapeutic outcome in RTOG 77-06, a phase III study for T1bN0M0(A2) and T2N0M0(B) prostate carcinoma. Int J Radiat Oncol Biol Phys. 40:1998;769-782
12. Martinez A.A., Kestin L.L., Stronberg J.S., et al. Interim report of image-guided conformal high-dose-rate brachytherapy for patients with unfavorable prostate cancer The William Beaumont phase dose-escalating trial. Int J Radiat Oncol Biol Phys. 47:2000;343-352
13. American Society for Therapeutic Radiation and Oncology Consensus Panel. Consensus statement Guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys. 37:1997;1035-1041
14. Lawton C.A., Won M., Pilepich M.V., et al. Long-term sequelae following external beam irradiation for adenocarcinoma of the prostate Analysis of RTOG studies 7506 and 7706. Int J Radiat Oncol Biol Phys. 21:1991;935-939
15. Deger S., Dinges S., Roigas J., et al. High-dose rate iridium192 afterloading therapy in combination with external beam irradiation for localized prostate cancer. Techn Urol. 3:1997;190-194
16. Brenner D.J., Hall E.J. Fractionation and protraction for radiotherapy of prostate carcinoma. Int J Radiat Oncol Biol Phys. 43:1999;1095-1101
17. Stromberg J., Martinez A., Gonzalez J., et al. Ultrasound-guided high dose rate conformal brachytherapy boost in prostate cancer Treatment description and preliminary results of a phase I/II clinical trial. Int J Radiat Oncol Biol Phys. 33:1995;161-171
18. Borghede G., Hedelin H., Holmang S., et al. Combined treatment with temporary short-term high dose rate iridium-192 brachytherapy and external beam radiotherapy for irradiation of localized prostate carcinoma. Radiother Oncol. 44:1997;237-244
19. 192Iridium prostate brachytherapy Feasibility report. Int J Radiat Oncol Biol Phys. 41:1998;525-533
20. Syed N.A.M., Puthawala A.A., Barth N., et al. High dose rate brachytherapy in the treatment of carcinoma of the prostate Preliminary results. J Brachytherapy Int. 13:1997;315-331
21. Roach M, Lu JD, Lawton LC, et al. A phase III trial comparing whole-pelvic (WP) to prostate only (PO) radiotherapy and neoadjuvant total androgen suppression (TAS): Preliminary analysis of RTOG 9413. Proceedings of the 43rd Annual ASTRO Meeting, 2001. p. 3
22. Seaward S.A., Weinberg V., Lewis P., et al. Improved freedom from PAS failure with whole pelvic irradiation for high-risk prostate cancer. Int J Radiat Oncol Biol Phys. 42:1998;1055-1062
23. Galalae R.M., Kovacs G., Schultze J., et al. Long-term outcome after elective irradiation of the pelvic lymphatics and local dose escalation using high-dose-rate brachytherapy for locally advanced prostate cancer. Int J Radiat Oncol Biol Phys. 52:2002;81-90
24. Kestin L.L., Goldstein N.S., Vicini F.A., et al. Treatment of prostate cancer with radiotherapy Should the entire seminal vesicles be included in the clinical target volume? Int J Radiat Oncol Biol Phys. 54:2002;686-697
25. Katcher J., Kupelian P.A., Zippe C., et al. Indications for excluding the seminal vesicles when treating clinically localized prostatic adenocarcinoma with radiotherapy alone. Int J Radiat Oncol Biol Phys. 37:1997;871-876
26. Kovacs G., Galalae R., Loch T., et al. Prostate preservation by combined external beam and HDR brachytherapy in nodal negative prostate cancer. Strahlenther Oncol. 175:(Suppl.):1999;87-88
27. Dinges S., Deger S., Koswig S., et al. High-dose rate interstitial with external beam irradiation for localized prostate cancer - Results of a prospective trial. Radiother Oncol. 48:1998;197-202
28. Kestin L., Vicini F., Martinez A.A., et al. Practical application of biochemical failure definitions What to do and when to do it. Int J Radiat Oncol Biol Phys. 53:2002;304-315